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In our professional lives, we have not witnessed a healthcare crisis of this magnitude and severity. As 
we proof this (March 30, 2020), COVID-19, caused by 
the SARS-CoV-2 virus and labeled a global pandemic 
by the World Health Organization, is sweeping across 
the globe—over 730 000 cases and 35 000 deaths, with 
cases reported in over 190 countries. These numbers will 
rise substantially in forthcoming weeks and months.
We will all be in the midst of national and locally 
driven crisis management plans that understandably 
will impact our routine practice as we prioritize acute 
care to the most vulnerable. Over and above this, we felt 
it timely to highlight a few areas where our discipline-
specific contribution can deliver a major impact.
First, for patients treated with glucocorticoids, it will 
be invaluable to reiterate “sick day rules” for our known 
patients with primary and secondary adrenal insufficiency 
taking glucocorticoid replacement therapy. As it relates to 
COVID-19, any patient with a dry continuous cough and 
fever should immediately double their daily oral gluco-
corticoid dose and continue on this regimen until the fever 
has subsided. Deteriorating patients and those who ex-
perience vomiting or diarrhea should seek urgent medical 
care and be treated with parenteral glucocorticoids (1).
More impactful will be the extension of these guide-
lines to the ~5% of patients in our populations taking 
chronic therapeutic corticosteroids by differing routes for 
underlying inflammatory conditions. The prevalence of 
adrenal insufficiency in these patients is high (~50%) ir-
respective of mode of delivery (2). Currently there is little 
evidence to guide us on when to intervene in terms of dur-
ation of prior corticosteroid exposure or on the impact of 
dose, either at a higher dose where supplemental steroid 
cover may not be necessary or a lower dose where ad-
renal suppression may not be as prevalent. In the interim, 
it seems logical, if not essential, that we identify all pa-
tients taking corticosteroids for whatever reason as high 
risk. We know from the published reports to date that 
these patients will be overrepresented in those at greatest 
risk of dying from COVID-19—the elderly and those 
with co-morbidities that include diabetes, hypertension, 
and chronic inflammatory disease (3,4). Moreover, those 
patients taking supraphysiologic doses of glucocortic-
oids may have increased susceptibility to COVID-19 as 
a result of the immunosuppressive effects of steroids, 
comorbidities of underlying immune disorders for which 
the steroids were prescribed, or immunomodulatory ac-
tions of other therapies prescribed in conjunction with 
glucocorticoids for the underlying disease. Reversing po-
tential adrenal failure as a cause of mortality with par-
enteral glucocorticoid therapy is easy and simple to do 
once the issue has been recognized. The intent here is to 
ensure that no patient with a history of prior exposure to 
chronic glucocorticoid therapy (>3 months) by whatever 
route should die without consideration for parenteral 
glucocorticoid therapy. As a community, we will be key 
to ensuring recognition, management, and implementa-
tion of these important measures.
In this context, it will be important to communicate 
the reason underpinning glucocorticoid use. Based on 







/article/105/5/1299/5814115 by guest on 07 Septem
ber 2021
1300  Kaiser et al  Response to COVID-19 J Clin Endocrinol Metab, May 2020, 105(5):1299–1301
prior experience in patients with acute respiratory dis-
tress syndrome and those affected with SARS and MERS 
(5), where glucocorticoid therapy was without benefit 
or associated with higher rates of invasive ventilation 
and mortality, the World Health Organization guidance 
is not to prescribe glucocorticoids (6). Physiological 
stress doses of hydrocortisone (50–100 mg intraven-
ously t.i.d) not pharmacological doses of other cortico-
steroids should be given.
Second, the impact on patients with pituitary or 
other neuroendocrine disease also needs to be con-
sidered. As for patients with primary adrenal insuffi-
ciency, many of these patients have hypopituitarism 
including secondary adrenal insufficiency, requiring 
stress dose glucocorticoid supplementation as previ-
ously noted. Moreover, these patients may also have 
diabetes insipidus, further compounding fluid and elec-
trolyte disorders and requiring careful monitoring and 
judicious water and electrolyte replacement to prevent 
hyponatremia or hypernatremia. This is particularly im-
portant in the context of increased insensible fluid loss 
associated with fever and tachypnea, combined with im-
paired ability for fluid intake with altered level of con-
sciousness (7).
Third, for patients with diabetes mellitus, whereas 
the risk of contracting a viral illness is no greater than 
those without diabetes mellitus, severity of disease from 
viral infections is notably greater. Recent published re-
ports from the Wuhan province in China (3,4) reveal 
that those with diabetes mellitus and hypertension 
were overrepresented among the most severely ill pa-
tients with COVID-19 and those succumbing to the 
disease. Whether this susceptibility to illness severity is 
especially greater in the case of COVID-19 or simply 
a reflection of the greater risk posed by diabetes re-
mains uncertain at this point. Current guidance from 
the Centers for Disease Control and Prevention for pre-
vention of COVID-19 for those with diabetes is no dif-
ferent than the general population, but the recognition 
that diabetes poses a greater risk for severity of illness 
should prompt health-care providers to be more vigi-
lant in the assessment of such patients who present with 
concerning symptoms (ie, shortness of breath, fever) (8).
Finally, as clinician scientists, we realize that re-
search and innovation will ultimately provide solutions 
to this crisis, whether through enhanced diagnostics, 
innovative therapies, or future vaccines. A potentially 
exciting endocrine-connected observation is the eluci-
dation of the mechanism of entry of SARS-CoV-2 into 
cells. Here, angiotensin-converting enzyme 2 (ACE2) 
is now established as the SARS-CoV receptor (9) but 
with conflicting data as to its translational relevance. It 
has been suggested that angiotensin-converting enzyme 
inhibitors/angiotensin receptor blockers might increase 
susceptibility and severity to COVID-19 through 
upregulation of ACE2 and thereby possibly explain the 
overrepresentation of hypertensive patients in patients 
dying from COVID-19 (10). Upregulation of ACE2 
might also explain the poor outcome in smokers versus 
nonsmokers, but it is important to stress that these are 
preliminary reports and should not result in changing 
prescribed medications at this stage (11). APN01 is a 
recombinant human ACE2 developed by APEIRON 
for the treatment of acute lung injury, acute respiratory 
distress syndrome, and pulmonary arterial hyperten-
sion; by slowing viral entry into cells and viral spread, 
it may be beneficial, and clinical trials are underway 
(12). Conversely, angiotensin II is known to stimulate 
alveolar epithelial cell apoptosis, and inhibition of this 
with angiotensin receptor 1 blockers such as losartan 
might reduce mortality from acute respiratory distress 
syndrome in COVID-19 infection (13).
Perhaps justifying greater excitement is the down-
stream transmembrane protease serine 2 required for 
SARS-CoV-2 viral spike protein priming and onward 
transmission (14). Camostat mesylate, a transmembrane 
protease serine 2 inhibitor, has been approved in Japan 
for the treatment of pancreatic inflammation and when 
tested on SARS-CoV-2 isolated from a patient prevented 
the entry of the virus into lung cells. Endocrine-related 
targets are at the forefront of discovery science as we 
collectively tackle this pandemic.
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